GlassScriptPhysician profile
Aaron Keith Starbuck
NPI 1336288034
$3,644.44
in general payments reported to CMS, 2019-2025
33 companies · $613 in 2025
The $613 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $581 · 2021: $743 · 2022: $602 · 2023: $566 · 2024: $540 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,717.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $491.19 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $435.56 | 2021-2025 | Vraylar, Ubrelvy, Liletta |
| Lilly USA, LLC | $429.81 | 2020-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $300.53 | 2020-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Novo Nordisk INC | $286.81 | 2020-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $265.86 | 2020-2025 | Farxiga |
| Amgen INC. | $208.51 | 2021-2025 | Evenity, Repatha, Otezla |
| Astellas Pharma US INC | $191.88 | 2020-2025 | Veozah |
| Pfizer INC. | $152.91 | 2020-2025 | |
| Glaxosmithkline, LLC. | $141.15 | 2021-2025 | Arexvy, Shingrix |
| Abbott Laboratories | $104.46 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $94.08 | 2020-2024 | Xarelto |
| Amarin Pharma, INC. | $85.31 | 2020-2021 | |
| Organon LLC | $59.52 | 2021-2025 | Nexplanon |
| Sanofi-Aventis U.S. LLC | $44.36 | 2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $37.76 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Sanofi Pasteur INC. | $28.94 | 2025 | |
| Supernus Pharmaceuticals, INC. | $26.42 | 2025 | Qelbree |
| Bausch Health US, LLC | $25.60 | 2022 | |
| Vanda Pharmaceuticals INC. | $23.84 | 2024 | Fanapt |
| Ani Pharmaceuticals, INC. | $22.25 | 2025 | Purified Cortrophin Gel |
| Lundbeck LLC | $20.60 | 2024 | Rexulti |
| Corium, LLC | $19.22 | 2025 | Azstarys |
| Seqirus USA INC | $18.38 | 2022 | |
| Cranial Technologies, INC | $17.50 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.93 | 2023 | Quviviq |
| Inspire Medical Systems, INC. | $15.89 | 2025 | Inspire |
| Dexcom, INC. | $15.69 | 2023 | Dexcom G6 Transmitter |
| Ultragenyx Pharmaceutical INC. | $14.52 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.45 | 2024 | |
| Exact Sciences Corporation | $12.79 | 2023 | Cologuard Collection Kit |
| Eisai INC. | $11.08 | 2021 | |
| Sumitomo Pharma America, INC. | $10.64 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Starbuck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.